Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to determine the efficacy of a portable biofeedback device on improving sleep latency and other sleep variables such as nocturnal awake time and daytime functioning in persons with primary insomnia.
There is evidence that when compared to normal controls, persons with insomnia exhibit increased cognitive and physiological arousal and higher overall metabolic rate during sleep, particularly at sleep onset. There is evidence that reducing this arousal may impact sleep latency and nocturnal awake time. Although relaxation treatments have been integrated into behavioral therapies, there are numerous barriers to their implementation in real world settings. The present study is designed to examine the effect of a portable biofeedback device designed to induce physiological relaxation as compared to an inactive sham control device condition in reducing sleep onset latency in persons with primary insomnia over a 4 week period at three separate research sites.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Portable Biofeedback | Device |
| Measure | Description | Time Frame |
|---|---|---|
| Sleep latency at 4 week follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| wake time after sleep onset (WASO) at 4 week follow-up | ||
| total awake time (SOL + WASO) at 4 week follow-up | ||
| Shifting from moderate/severe insomnia to mild/no insomnia (Insomnia Severity Index)at 4 week follow-up |
Not provided
Inclusion Criteria:
Between the ages of 18-55
Met DSM-IV-TR criteria for Primary Insomnia as measured by the:
Demonstrate Sleep Onset Latency of >=45 minutes on >= 3 nights per week greater than or equal to 6 days over the 2 week period.
A mean SOL >= 30 minutes over the 2 week period between Screening and Baseline visits.
Residential stability (1 year) and means to travel to appointments.
Willing to provide the name and contact information of a secondary contact person.
Off insomnia medications for at least one week prior to randomization and no more than 2 days of use during the first week of baseline.
Ability to read in English.
Provision of informed consent.
Willing to comply with daily protocol.
Ability to obtain a reading on the device.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jack Edinger, Ph.D. | Duke Unversity Medical Center | Principal Investigator |
| Charles Morin, Ph.D. | University of Laval | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Recruiting | Durham | North Carolina | 27710 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 10617176 | Background | Morin CM, Hauri PJ, Espie CA, Spielman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 1999 Dec 15;22(8):1134-56. doi: 10.1093/sleep/22.8.1134. |
| Label | URL |
|---|---|
| Sleep website | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D007319 | Sleep Initiation and Maintenance Disorders |
| ID | Term |
|---|---|
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Daytime functioning at 4 week follow-up |
| D001523 |
| Mental Disorders |